Biopharmaceutical therapies and cardiovascular innovations by Mineralys (MLYS)

  • Emilio Ghigini
  • 10.06.2026
Mineralys Therapeutics stock consolidates near $24.55 as weekly rebound slows amid ongoing technical pressure
Mineralys Therapeutics is prioritizing the advancement of science in hypertension during Alzheimer's and Brain Awareness Month.The company states that hypertension is a key risk factor for long ...
  • Ezequiel Gomes
  • 08.06.2026
Mineralys Therapeutics stock edges lower amid oversold conditions and consolidation risk in $21–$25 range
Mineralys Therapeutics will feature a new post hoc analysis of proteomic data from the Launch-HTN and Advance-HTN trials of lorundrostat in a late-breaking poster presentation on June 14, the ...
  • Ashutosh Sureka
  • 04.11.2025
Mineralys Therapeutics to release Q3 financial results on November 10
Mineralys Therapeutics announced it will release its third-quarter financial results after the financial markets close on Monday, November 10, 2025. Stakeholders and investors are anticipating ...